Clinical trials: Urticaria Chronic
Chronic Spontaneous Urticaria
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines
The purpose of this study was to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) in adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in…
- Trial name
- REMIX-1 (NCT05030311)
- Testing
- LOU064 25 mg (b.i.d), LOU064 25 mg (b.i.d) as a tablet.
- Where
- 112 sites in United States, Argentina and 17 more
- Volunteers
- 470 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
A Real-world Study to Assess Safety and Effectiveness of Xolair® in Pediatric Chronic Spontaneous Urticaria in China
This non-interventional, multi-center, prospective post-approval study aims to provide safety and effectiveness data of Xolair® in Chinese adolescents with Chronic Spontaneous Urticaria who remain symptomatic despite H1…
- Trial name
- NCT06053801
- Testing
- Xolair
- Where
- 10 sites in China
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria, Angioedema
Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
This study will assess the impact of omalizumab on the quality of life improvement when added to the standard therapy in refractory patients suffering from chronic spontaneous urticaria and angioedema.
- Trial name
- X-ACT (NCT01723072)
- Testing
- Omalizumab
- Where
- 25 sites in Germany
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
A Study to Explore the Efficacy and Safety of HWH486 in Adults With Chronic Spontaneous Urticaria
This is a multicenter, randomized, double-bind and placebo-controlled phase IIa dose-finding study to assess the safety and efficacy of HWH486 in adults with chronic spontaneous urticaria (CSU).
- Trial name
- NCT06295302
- Testing
- HWH486
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hubei Biological Medicine Industrial Technology Institute Co., Ltd.
Chronic Spontaneous Urticaria (CSU), Healthy Volunteers
Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2).
This is a randomized, double-blind, placebo-controlled phase 1b clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of Alpha-0261 Tablets in healthy Chinese adults and in patients with…
- Trial name
- NCT07684560
- Testing
- Alpha-0261
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AlphaMol Science Ltd. (Shanghai)
Chronic Idiopathic Urticaria
Etanercept for the Treatment of Chronic Urticaria
The purpose of this study is to evaluate the safety and efficacy of etanercept for patients with chronic idiopathic urticaria unresponsive to antihistamines.
- Trial name
- EtanerceptCIU (NCT01030120)
- Testing
- etanercept
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Utah
Chronic Idiopathic Urticaria
Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria
This is a single center, non-comparative exploratory study, to investigate the effect of omalizumab over a 3-month treatment period in adult (≥18 years) patients with chronic idiopathic urticaria who had remained symptomatic…
- Trial name
- NCT02814630
- Testing
- Xolair
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Asthma Inc Clinical Research Center
Urticaria
A Study of the Use of Methotrexate in the Treatment of Chronic Idiopathic Urticaria
The purpose of this study is to determine whether methotrexate produces significant improvement in chronic idiopathic urticaria, compared with placebo
- Trial name
- NCT00189878
- Testing
- Methotrexate (drug)
- Volunteers
- 3 people
- Sponsor
- Barnsley Hospital
Chronic Spontaneous Urticaria
Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria
The primary objective of this study is to evaluate the efficacy of tirabrutinib in reducing disease activity in participants with chronic spontaneous urticaria (CSU) with respect to change from baseline in urticaria activity…
- Trial name
- NCT04827589
- Testing
- Tirabrutinib
- Sponsor
- Gilead Sciences
Chronic Spontaneous Urticaria
Mepolizumab for the Treatment of Chronic Spontaneous Urticaria
This is an exploratory study designed to generate preliminary data in evaluating the efficacy of Nucala in the treatment of chronic spontaneous urticaria.
- Trial name
- NCT03494881
- Testing
- Nucala
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Chronic Inducible Urticaria, Cold Urticaria
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
The purpose of this Phase 3, randomized, double-blind, placebo-controlled study is to assess the activity and safety of barzolvolimab compared to placebo in participants with cold induced urticaria or symptomatic dermographism…
- Conditions
- Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
- Trial name
- NCT07266402
- Testing
- Barzolvolimab
- Where
- 72 sites in United States, Germany and 5 more
- Volunteers
- 240 people
- Sponsor
- Celldex Therapeutics
Urticaria
Effect of Anti-IgE in Chronic Urticaria
This study is being done to find out if a drug called Xolair (omalizumab), an anti-IgE antibody, is safe and effective for people with chronic urticaria (hives) with persistent symptoms in spite of taking antihistamines.
- Trial name
- NCT00130234
- Testing
- Xolair® (Omalizumab)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Chronic Spontaneous Urticaria
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).
- Trial name
- NCT06873516
- Testing
- EVO756
- Where
- 53 sites in United States, Canada and 1 more
- Volunteers
- 182 people
- Sponsor
- Evommune, Inc.
Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Inflammatory symptoms of Cryopyrin-Associated Periodic Syndrome (CAPS) are due to mutations in a the NLRP-3 gene (previously known as Cold Induced Autoinflammatory Syndrome-1 or CIAS1).
- Conditions
- Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn
- Trial name
- NCT00288704
- Testing
- rilonacept 160 mg
- Where
- 24 sites in United States
- Volunteers
- 104 people
- Sponsor
- Regeneron Pharmaceuticals
Inflammation, Familial Mediterranean Fever
Interleukin-1 Trap to Treat Autoinflammatory Diseases
Autoinflammatory diseases are illnesses characterized by episodes of inflammation that, unlike autoimmune disorders, lack the production of high titer autoantibodies or antigen-specific T cells.
- Conditions
- Inflammation, Familial Mediterranean Fever, Still's Disease, Adult-Onset
- Trial name
- NCT00094900
- Testing
- IL-1 Trap
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Chronic Spontaneous Urticaria
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the…
- Trial name
- NCT05513001
- Testing
- LOU064 (blinded), LOU064 (open label)
- Where
- 208 sites in United States, Argentina and 28 more
- Volunteers
- 696 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria
The study is being conducted to evaluate the efficacy, and safety of HRS-3095 with Chronic Spontaneous in adults, and to explore the reasonable dosage of HRS-3095 for Chronic Spontaneous Urticaria.
- Trial name
- NCT07613866
- Testing
- HRS-3095 Tablet
- Where
- 2 sites in China
- Volunteers
- 190 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Urticaria, Angioedema
Significance of an Elimination and Provocation Diet in Patients With Chronic Urticaria
Patients with chronic urticaria undertake a five week elimination diet (pseudoallergen free diet). The efficacy of the diet will be determined by symptom score, by the use of rescue medication (oral antihistamines and…
- Trial name
- NCT00385372
- Testing
- elimination diet, provocation diet
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- University Hospital Muenster
Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered single and multiple doses of EDP-978 in…
- Trial name
- NCT07540910
- Testing
- EDP-978
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Chronic Urticaria
Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
The purpose of the study is to compare the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability, and immunogenicity of TEV-45779 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria…
- Trial name
- NCT04976192
- Testing
- TEV-45779, XOLAIR® Injection
- Where
- 9 sites in United States
- Volunteers
- 608 people
- Sponsor
- Teva Pharmaceuticals USA